

## MIRA INFORM REPORT

Report No. :	537382
Report Date :	31.10.2018

### IDENTIFICATION DETAILS

Name :	COOPERSURGICAL, INC.
Registered Office :	251 Little Falls Drive, Wilmington, New Castle, De, 19808
Country :	United States
Date of Incorporation :	20.11.1990
Legal Form :	Corporation
Line of Business :	Develops, manufactures, and markets medical instruments, devices, and disposables with a focus on women's health care and minimally invasive surgery.
No. of Employees :	500 (The company is part of a group that has 12,000 employees).

### RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23<sup>rd</sup> January 2017)

MIRA's Rating :	A+
-----------------	----

Credit Rating	Explanation	Rating Comments
A+	Low Risk	Business dealings permissible with low risk of default

Status :	Good
Payment Behaviour :	Regular
Litigation :	Exist

#### NOTES :

Any query related to this report can be made on e-mail : [infodept@mirainform.com](mailto:infodept@mirainform.com) while quoting report number, name and date.

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**ECGC Country Risk Classification List**

Country Name	Previous Rating (30.06.2018)	Current Rating (30.09.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**UNITED STATES - ECONOMIC OVERVIEW**

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

The Federal Reserve Board (Fed) announced plans in December 2012 to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA

## **STATUTORY INFORMATION**

Order	Cooper Surgical
Address in the order	95, Corporate Drive, Trumbull CT 06611
Legal Name	COOPERSURGICAL, INC.
Trade Name	COOPERSURGICAL, INC.
ID	ID
ID Details	2247088
Creation Date	1990
Incorporation Date	11/20/1990
Legal Address	251 LITTLE FALLS DRIVE, WILMINGTON, NEW CASTLE, DE, 19808, USA
Operative Address	95 Corporate Drive Trumbull, CT 06611 United States
Telephone	203-601-5200
Fax	800-262-0105
Legal Form	CORPORATION
E-Mail	-
Registered In	DELAWARE
Website	www.coopersurgical.com
Contact	Dr. Robert D. Auerbach - President
Staff	500 (The company is part of a group that has 12,000 employees).
Activity	NAICS Code: 423450, Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers

## **BANKS**

Name of Bank	Reported Amount
BANK OF AMERICA	

## **HISTORY**

### History

The company was founded in 1990 and is based in Trumbull, Connecticut.

On May 31, 2016, CooperSurgical completed the acquisition of Reprogenetics UK, a U.K.-based genetics laboratory specializing in service offerings of preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) used during the IVF process.

On May 25, 2016, CooperSurgical completed the acquisition of Recombine Inc., a United States based clinical genetic testing company specializing in carrier screening. Recombine operates in the IVF market and creates comprehensive genetic carrier screening tests.

On May 4, 2016, CooperSurgical completed the acquisition of Kivex Biotec A/S (K-Systems), a Danish manufacturer and distributor of equipment, including workstations and incubators for IVF clinics.

On March 31, 2016 CooperSurgical completed the acquisition of Genesis Genetics Inc., a United States based genetics laboratory specializing in PGS and PGD used during the IVF process.

### Key Developments

CooperSurgical Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended October 31, 2017; Provides Consolidated Revenue Guidance for the First Quarter and Full Year of Fiscal 2018

Dec 7 17

CooperSurgical Inc. announced unaudited earnings results for the fourth quarter and full year ended October 31, 2017. For the quarter, the company posted revenues of \$123 million, up 15% as reported, up 7% pro forma, driven by organic growth in acquisitions. Operating income improved 15.4% to 22.4%, driven by operating expense leverage. For the full year, the company posted revenues were \$464.9 million, up 19% or 4% pro forma. For the fiscal 2018, the company expects revenues of \$650 million to \$665 million at CooperSurgical, or roughly 40% to 43% as reported growth, 2% to 4% pro forma growth. The company expects first quarter of 2018 revenues for consolidated CooperSurgical to be around \$150 million, with PARAGARD being roughly \$34 million of that. This \$34 million would be a year-over-year decline of roughly 25%.

Parent Company

CooperSurgical Reports Revenue Results for the First Quarter Ended January 31, 2017; Provides Revenue Guidance for the Year 2017

Mar 2 17

CooperSurgical reported revenue results for the first quarter ended January 31, 2017. For the period, the company's revenue \$109.8 million, up 29% from last year's first quarter, up 3% pro forma. For the year 2017, the company expects revenue to be \$470 million - \$480 million.

CooperSurgical Inc. operates as a subsidiary of:  
Cooper Medical, Inc.  
919 Wyckoff Avenue  
Ridgewood, NY 11385  
United States

## **PRINCIPAL ACTIVITY**

General Description

CooperSurgical Inc. develops, manufactures, and markets medical instruments, devices, and disposables with a focus on women's health care and minimally invasive surgery.

Service/Product Description

It offers surgical products, such as C-section retractors, hysterectomy/laparoscopic instruments, laparoscopic port-site closures, pelvic procedure kits, secondary trocars, and self-retaining retractors, as well as female sterilization, hernia repair, laparoscopic smoke evacuation, wound protection, and uterine manipulation devices. It offers clinical/practice based devices, such as biopsy punches, cervical/endocervical samplers, endometrial samplers, H/S catheters, LEEP systems and accessories, pessaries, bartholin cyst catheters, breast biopsy needles, cervical cryosurgery systems, cervical tenacula systems, diaphragms, endometrial curettes, fetal monitors, forceps, IUD hooks, stainless lateral wall retractors, LEEP instruments and essentials, needle holders, ophthalmic cryosurgery systems, stainless steel scissors, tissue hooks, and sounds and dilators, as well as colposcopy, hysteroscopy, intrauterine insemination, cryoablation, specula, fertility assessment, urodynamics, and other systems; labor and delivery systems; adult and neonatal care systems; and assisted reproductive technology systems. Its products are used for various procedures ranging from basic annual gynecological exams to complex surgeries. It serves obstetricians,

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Sales	gynecologists, physicians, hospitals, clinics, biomedical engineers, healthcare administrators, supply chain professionals, assisted reproductive technology clinics, and other healthcare professionals in the United States and internationally.
Operations Area	Wholesale
Imports From	National and International
Export To	CHINA, LITHUANIA
Employees	MEXICO
Payments with Suppliers	500 employees (The company is part of a group that has 12,000 employees).
	Regular

Brands  
Brand

Comments

COOPER SURGICAL

-

Clients

Name of Client

Country

Comments

B Y P Medical SA De Cv

MEXICO

-

Comments

-

Suppliers

Supplier Name

Country

Comments

STENGEL LT

LITHUANIA

-

Pacific Medical (Hong Kong) Co.,  
Ltd.

CHINA

-

Comments

-

## **LOCATION**

Headquarters

95 Corporate Drive Trumbull, CT 06611 United States

Branches

Coopersurgical, Inc.  
75 CORPORATE DR TRUMBULL, CT, 06611-1350  
United States

Coopersurgical, Inc.  
393 SOUNDVIEW RD GUILFORD, CT, 06437-2970  
United States

Coopersurgical, Inc.  
825 WURLITZER DR NORTH TONAWANDA, NY,  
14120-3041 United States

## **GROUP STRUCTURE AND SUBDIARY COMPANIES**

Listed at the stock exchange	NO
Capital	NA
Shareholders (%)	The company does not disclose information on shareholders. The following information has been provided by private sources: CooperSurgical Inc. operates as a subsidiary of: Cooper Medical, Inc. 919 Wyckoff Avenue Ridgewood, NY 11385 United States
Management	The company's ultimate parent is: The Cooper Companies Inc. 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 United States Dr. Robert D. Auerbach - President Mr. Alan T. Tucker - Chief Financial Officer Mr. Kerry Blair - Vice President of Operations Mr. Kim Duncan - Senior Director of Investor Relations Dr. Russell S. Heinrich Ph.D. - Vice President of R&D
Subsidiary Companies	Reprogenetics UK United Kingdom
	Recombine Inc. United States
	Kivex Biotec A/S Denmark
Related Companies	Genesis Genetics Inc. United States TCC Acquisition Corp. 6140 Stoneridge Mall Road

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Suite 590  
Pleasanton, CA 94588  
United States

Ocular Sciences Puerto Rico, Inc  
500 Road 584  
Amuelas Industrial Park  
Juana Diaz, PR 00795  
United States

CooperVision, Inc.  
209 High Point Drive  
Suite 100  
Victor, NY 14564  
United States

## **FINANCIAL INFORMATION**

General Description	We attach the parent's last financial statements.
	The company does not make its financial statements public. The following information has been provided by private sources:
Year/Currency	USD 2017
Sales	450.000.000
Money Flow	Normal
Import Fob Dollar Year	Amount
There are not Import Fob Dollar informed	
Export Fob Dollar Year	Amount
There are not Export Fob Dollar informed	

## **LEGAL FILINGS**

Lawsuits	UPTON v. TEVA PHARMACEUTICALS USA, INC. et al Plaintiff: TAMMARA UPTON Defendant: TEVA PHARMACEUTICALS USA, INC., TEVA BRANDED PHARMACEUTICAL PRODUCTS
----------	---

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

R&D, INC., TEVA WOMEN'S HEALTH, INC., THE  
COOPER COMPANIES, INC. and  
COOPERSURGICAL, INC.

Case Number: 2:2018cv04449

Filed: October 15, 2018

Court: Pennsylvania Eastern District Court

Presiding Judge: HARVEY BARTLE

Nature of Suit: P.I.: Health Care/Pharmaceutical

Personal Injury Product Liability

Cause of Action: 28:1332

Jury Demanded By: Both

REITH v. TEVA PHARMACEUTICALS USA, INC. et al  
Plaintiff: KATHRYN REITH

Defendant: TEVA BRANDED PHARMACEUTICAL  
PRODUCTS R&D, INC., TEVA WOMEN'S HEALTH,  
INC., THE COOPER COMPANIES, INC.,  
COOPERSURGICAL, INC. and TEVA  
PHARMACEUTICALS USA, INC.

Case Number: 2:2018cv03987

Filed: September 14, 2018

Court: Pennsylvania Eastern District Court

Presiding Judge: GERALD A MCHUGH

Nature of Suit: P.I.: Health Care/Pharmaceutical

Personal Injury Product Liability

Cause of Action: 28:1332

Jury Demanded By: Both

ROUTT v. TEVA PHARMACEUTICALS USA, INC. et al  
Plaintiff: CHRISTI ROUTT

Defendant: TEVA PHARMACEUTICALS USA, INC.,  
TEVA BRANDED PHARMACEUTICAL PRODUCTS  
R&D, INC., TEVA WOMEN'S HEALTH, INC., THE  
COOPER COMPANIES, INC. and  
COOPERSURGICAL, INC.

Case Number: 2:2018cv03996

Filed: September 14, 2018

Court: Pennsylvania Eastern District Court

Presiding Judge: MICHAEL M BAYLSON

Nature of Suit: P.I.: Health Care/Pharmaceutical

Personal Injury Product Liability

Cause of Action: 28:1441

Jury Demanded By: Both

WALLIS v. TEVA PHARMACEUTICALS USA, INC. et  
al

Plaintiff: LAUREN WALLIS

Defendant: TEVA PHARMACEUTICALS USA, INC.,  
TEVA BRANDED PHARMACEUTICAL PRODUCTS

Trademarks

R&D, INC., THE COOPER COMPANIES, INC., TEVA  
WOMEN'S HEALTH, INC. and COOPERSURGICAL,  
INC.

Case Number: 2:2018cv03990

Filed: September 14, 2018

Court: Pennsylvania Eastern District Court

Presiding Judge: GENE EK PRATTER

Nature of Suit: P.I.: Health Care/Pharmaceutical

Personal Injury Product Liability

Cause of Action: 28:1441

Jury Demanded By: Both

ASTRINGYN

astringents for gynecological use

Owned by: CooperSurgical, Inc.

Serial Number: 74137499

ELEVEST

laproscopic surgical tools, namely, kits comprising a  
suture passer, suture, a grasper, a viewing device, and  
a suture template...

Owned by: CooperSurgical, Inc.

Serial Number: 75556244

COOPERSURGICAL HYSTEROSCOPE

surgical instrument; namely an instrument for  
resectioning the uterus

Owned by: CooperSurgical, Inc.

Serial Number: 74152198

LSMP

Surgical instruments, namely, retractor systems,  
retractor rings, elastic stays, elastic stay hooks

Owned by: CooperSurgical, Inc.

Serial Number: 78314348

Image Trademark

Surgical instruments, namely, retractor systems,  
retractor rings, elastic stays, elastic stay hooks

Owned by: CooperSurgical, Inc.

Serial Number: 78314354

REFINING THE ART OF SURGERY

Surgical instruments, namely, retractor systems,  
retractor rings, elastic stays, elastic stay hooks

Owned by: CooperSurgical, Inc.

Serial Number: 78314352

Suture Passer Guides and Related Kits and Methods

Publication number: 20130165956

Abstract: A suture passer guide that includes an

Patents Registered

elongate member having a longitudinal axis and defining a first proximal opening and a first distal opening. The first proximal and distal openings are substantially aligned with one another such that a suture passer can be extended through the first proximal and distal openings at an acute angle relative to the longitudinal axis of the elongate member. The suture passer guide can be configured to be passed through a central lumen of an endoscopic port.

Type: Application

Filed: December 21, 2012

Publication date: June 27, 2013

Applicant: CooperSurgical, Inc.

Inventor: CooperSurgical, Inc.

#### Suture Passers and Related Methods

Publication number: 20130218175

Abstract: A suture passer includes an elongate tube defining a central lumen and having a beveled distal end region and a grasping member comprising a first elongate member and a first jaw extending distally from the first elongate member. The grasping member is sized to be disposed within the elongate tube and is capable of being extended from the elongate tube in a manner such that the first elongate member and the first jaw are disposed at least partially distal to the beveled distal end region of the elongate tube. The grasping member is further capable of being retracted within the elongate tube in a manner such that the first elongate member is located substantially within the central lumen of the elongate tube and the first jaw substantially covers an opening of the beveled distal end region of the elongate tube.

Type: Application

Filed: January 7, 2013

Publication date: August 22, 2013

Applicant: COOPERSURGICAL, INC.

Inventor: COOPERSURGICAL, INC.

#### Uterine Manipulators and Related Components and Methods

Publication number: 20120109146

Abstract: A colpotomizer cup includes a cup body and a sleeve. The cup body is configured to receive a cervix. The sleeve is connected to the cup body and includes a locking member for locking the colpotomizer cup in a predetermined position along a length of the uterine manipulator handle.

Type: Application

Renewals

Filed: November 1, 2010

Publication date: May 3, 2012

Applicant: COOPERSURGICAL, INC.

Inventors: Robert D. Auerbach, Charles Sherts, Peter K. Arneson, Kerry Blair

No found.

UCC (Uniform Commercial Code)

No found.

OFAC Sanctions List Search

The company is not listed in the OFAC Sanctions List.

## **SUMMARY**

Summary

Founded in 1990, COOPERSURGICAL, INC. is an organization in the Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers Industry headquartered in Trumbull, CT. The company has 500 regular employees and generates an estimated USD\$450 million in annual revenue. It operates nationally and internationally, mainly exporting to Mexico. It is ACTIVE in business with no negative records.

## **INTERVIEW**

First Name

-

Position

-

Comments

We called number 203-601-5200 several times and received no answer.

**FOREIGN EXCHANGE RATES**

Currency	Unit	Indian Rupees
US Dollar	1	INR 73.57
UK Pound	1	INR 94.18
Euro	1	INR 83.71
USD	1	INR 74.04

**Note :** Above are approximate rates obtained from sources believed to be correct

**INFORMATION DETAILS**

<b>Analysis Done by :</b>	NIS
<b>Report Prepared by :</b>	SDA

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**RATING EXPLANATIONS**

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)